&nbsp;

CCOSTQBPGuidanceRecommend.pdf

Oct 2017

Regimen

PACL(W)+BEVA

Cancer Type:

Gynecologic,

Ovary

Intent: Palliative

Funding:

New Drug Funding Program

Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Drugs Used:

PACLitaxel,

Quick Link(s):

Regimen Monograph

Regimen

PGLDX+BEVA

Cancer Type:

Gynecologic,

Ovary

Intent: Palliative

Funding:

New Drug Funding Program

Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer

New Drug Funding Program

Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

pegylated liposomal DOXOrubicin,

Drugs Used:

Quick Link(s):

Regimen Monograph

Regimen

TOPO(W)+BEVA

Cancer Type:

Gynecologic,

Ovary

Intent: Palliative

Funding:

New Drug Funding Program

Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Drugs Used:

topotecan,

Quick Link(s):

Regimen Monograph

Sep 2023

Regimen

TOPO+BEVA

Cancer Type:

Gynecologic,

Ovary

Intent: Palliative

Funding:

New Drug Funding Program

Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Drugs Used:

topotecan,

Quick Link(s):

Regimen Monograph

Sep 2023

Document

DAP Locations HTML

Oct 2017

Document

DAP Locations XML

Oct 2017

Statistical Reports

Ontario Cancer Screening Performance Report 2016

*/ For the most recent data, refer to the Ontario Cancer Screening Performance Report 2023.

Dec 1969

Ontario Cancer Profiles

Statistical Reports

Cancer Risk Factors & Screening Among Inuit in Ontario and Other Canadian Regions

Sep 2017

Document

Dap Locations XML 3

Oct 2017

Document